Kintara Therapeutics, Inc. Stock Price, News & Analysis

Kintara Therapeutics (Nasdaq: KTRA) has announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The company will present data on its investigational drug VAL-083, focused on treating RELA fusion-positive ependymoma and recurrent glioblastoma. Two abstracts will be shared: one detailing case studies of VAL-083 in patients with ependymoma and glioma under an expanded access program, and another highlighting findings from 24 recurrent glioblastoma patients. Kintara is dedicated to developing innovative cancer therapies, with VAL-083 currently being advanced in the GBM AGILE registrational study.

Kintara Therapeutics (Nasdaq: KTRA) announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 14-19 in Orlando. The company will present two posters focused on its lead program, VAL-083, aimed at treating recurrent glioblastoma. The presentations, on April 17, will cover case reports of RELA fusion-positive ependymoma and VAL-083’s application in glioblastoma patients under expanded access. Kintara, based in San Diego, is dedicated to developing novel cancer therapies to address significant medical needs.

Kintara Therapeutics, Inc. (NASDAQ: KTRA) announced its participation in two significant conferences in March 2023. At the 35th Annual ROTH Conference in Dana Point, CA, CEO Robert E. Hoffman will provide a corporate update on March 13 at 10:30 AM PT. Concurrently, at the 4th Annual Glioblastoma Drug Development Summit in Boston, MA, Dr. Dennis Brown and Greg Johnson will discuss Kintara's VAL-083 program for glioblastoma on March 15 at 4:00 PM ET. Kintara focuses on developing innovative cancer therapies, specifically VAL-083 for glioblastoma and REM-001 Therapy for cutaneous metastatic breast cancer.

Kintara Therapeutics, Inc. (NASDAQ: KTRA) reported its fiscal second-quarter financial results for the period ending December 31, 2022. The company has cash reserves of approximately $4.9 million and experienced a net loss of about $3.5 million, a decrease from $5.9 million in the same period last year. Key developments include receiving FDA Orphan Drug Designation for VAL-083, which targets untreated childhood brain cancer, and Fast Track Designation for REM-001 therapy in metastatic breast cancer. Kintara paused the REM-001 program to preserve cash, expecting to save around $3 million in 2023. Upcoming data from the GBM AGILE Study is anticipated by year-end.